Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Overview
Date Founded

1990

Headquarters

1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA, CA, 94501

Type of Company

Public

Employees (Worldwide)

55

Industries

Biotechnology
Hospitals & Patient Services
Medical Support Services

Company Description

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Contact Data
Trying to get in touch with decision makers at Lineage Cell Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial & Accounting Officer

Global Head-Research & Development

Senior Vice President, Clinical & Medical Affairs

Vice President, Business Development

Chief Executive Officer, Cell Cure Neurosciences

Director

Director, Investor Relations

Director

Patent Counsel

Board of Directors

General Partner at Greenway Partners LP

President/Chief Compliance Officer at Broadwood Capital, Inc.

Research Fellow at Gruter Institute for Law and Behavioral Research

Former President & Chief Executive Officer at Questcor Pharmaceuticals, Inc.

Chief Executive Officer at Lineage Cell Therapeutics, Inc.

President at Mulroy Advisors LLC

Former Chief Financial Officer at STAAR Surgical Co.

Chief Compliance Officer at Quintiles, Inc. (California)

Paths to Lineage Cell Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Lineage Cell Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Broadwood Capital conducts in-depth fundamental research to make investment decisions andrecommendations. The firm's research includes analysis of “micro” variables such as company,industry, and sector specific business drivers, as well as “macro” considerations such as global economic growth drivers, monetary and fiscal policies, and geopolitical developments. They employ the following strategies: Buy and Hold; Diversification; Fundamental Value; Hedging; Leverage; Low Portfolio Turnover; Shareholder Activism; Short Selling; and Tax Efficiency.

Details Hidden

Greenway Partners manages a traditional long/short equity hedge fund. They invest primarily in the stocks of US small-cap companies in the health technology sector

Details Hidden

Defender Capital utilizes fundamental analysis techniques in formulating investment advice or managing assets for clients. The firm takes a long-term investment approach and offers a US core all-cap equity strategy which adheres to a disciplined, research-driven investment process that results in low portfolio turnover and tax efficiency. They focus on selecting individual equities, as opposed to mutual funds and money managers.

Recent Transactions
Details Hidden

Lineage Cell Therapeutics, Inc. purchases Asterias Biotherapeutics, Inc.

Details Hidden

Juvenescence Ltd. purchases Agex Therapeutics, Inc. from Lineage Cell Therapeutics, Inc.

Details Hidden

Arsenal Capital Management LP, BioIVT LLC purchase Ascendance Biotechnology, Inc. from Lineage Cell Therapeutics, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onLineage Cell Therapeutics, Inc. issued . USD Common Stock

Auditor

Advised onLineage Cell Therapeutics, Inc. issued . USD Common Stock

Escrow Agent

Advised onLineage Cell Therapeutics, Inc. issued . USD Common Stock

Managing Director

Advised onLineage Cell Therapeutics, Inc. issued . USD Common Stock

Legal Advisor

Advised onLineage Cell Therapeutics, Inc. issued . USD Common Stock

Legal Advisor

Advised onLineage Cell Therapeutics, Inc. issued . USD Common Stock

Advisors & Consultants
Consultant

Former Chief Financial Officer & Director at Asterias Biotherapeutics, Inc.

Consultant

Chief Financial Officer & Principal Accounting Officer at Longboard Pharmaceuticals, Inc.

Advisor

Former President-Regenerative Medicine at Shire Plc

Clients

CJ Corp. engages in managing investments. The company through its subsidiaries operates in the following businesses: Food and Food services, Retail and Logistics, Entertainment and Media, Infrastructure, and Life Science. The company was founded on August 1, 1953 and is headquartered in Seoul, South Korea.

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Key Stats and Financials As of 2020
Market Capitalization
$428M
Total Enterprise Value
$225M
Earnings Per Share
$-0.14
Net Profit
$-20.6M
EBITDA
$-24.7M
EBITDAMargin
-3,193.92%
Total Debt
$3.3M
Total Equity
$95.1M
Enterprise Value / Sales
290.64x
TEVNet Income
-10.88x
Debt TEV
0.01x
Three Year Compounded Annual Growth Rate Of Revenue
-39.31%
Revenue
$773K
Investors
Details Hidden

Chairman & Chief Executive Officer at ChemioCare USA, Inc.

Suppliers
Wisconsin Alumni Research Foundation Other Business & Consulting Services | Madison, Wisconsin

Since its founding in 1925, WARF has served the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to leading companies in Wisconsin, the United States and worldwide. In this way, WARF also facilitates the use of UW-Madison research for the maximum benefit of society. WARF distributes the income from commercial licenses to the UW-Madison, the inventors and their departments. Each year, WARF contributes more than $45 million to fund additional UW-Madison research. The university refers to WARF's annual gifts as its "margin of excellence" funding.

A unique educational institution

University of California Holding Companies | Oakland, CA

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Competitors
Astellas Pharma, Inc. Pharmaceuticals - Tokyo, Jpn

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company is headquartered in Tokyo, Japan.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Lineage Cell Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Lineage Cell Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Lineage Cell Therapeutics, Inc..